DPM3 Inhibitors
DPM3 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the DPM3 (Dolichyl-Phosphate Mannose Synthase Subunit 3) protein. DPM3 is a crucial component of the dolichol-phosphate mannose (DPM) synthase complex, which plays an essential role in glycosylation, particularly in the production of dolichol-phosphate mannose. This molecule serves as a glycosyl donor in the biosynthesis of glycoproteins and glycolipids. The DPM complex is composed of three subunits: DPM1, DPM2, and DPM3, with DPM3 being important for stabilizing the entire complex and anchoring it to the endoplasmic reticulum (ER) membrane. Inhibiting DPM3 disrupts the function of the DPM synthase complex, which affects the availability of dolichol-phosphate mannose, thereby impacting glycosylation processes essential for proper protein folding, cellular signaling, and membrane structure.
The mechanism of DPM3 inhibitors generally involves blocking the assembly or stability of the DPM synthase complex by interacting with the DPM3 subunit. These inhibitors may bind to regions of DPM3 responsible for anchoring the complex to the ER membrane or for stabilizing the catalytic DPM1 subunit, thereby preventing the proper synthesis of dolichol-phosphate mannose. Structurally, DPM3 inhibitors might be designed to mimic the interactions that stabilize the DPM complex or to interfere with key binding sites on DPM3 that are necessary for its functional role. By studying DPM3 inhibitors, researchers can gain insights into the critical role of glycosylation in cellular processes and explore how disruptions in glycan biosynthesis affect cellular homeostasis, protein function, and membrane integrity. These inhibitors serve as important tools for understanding the broader implications of glycosylation in cellular biology and the specific role of the DPM3 subunit in maintaining these biochemical pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin Gallate may downregulate DPM3 by hindering the activity of specific transcription factors responsible for its gene expression, potentially through the inhibition of DNA methyltransferases. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol could decrease the expression of DPM3 by activating SIRT1, which might lead to the deacetylation of histones at the DPM3 gene promoter, resulting in a tighter chromatin conformation that is less accessible for transcription. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
DL-Sulforaphane may reduce the expression of DPM3 by altering the expression of NRF2-dependent genes, leading to changes in the cellular redox state that could extend to the expression of glycosylation-related genes like DPM3. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Disulfiram could inhibit the expression of DPM3 by chelating trace metals essential for the function of enzymes that regulate gene expression and thus indirectly decreasing the transcriptional activity of the DPM3 gene. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate may lead to the downregulation of DPM3 by inhibiting histone deacetylases, promoting a more open chromatin structure at other gene loci while simultaneously repressing transcription at the DPM3 site. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid might reduce DPM3 expression by inhibiting histone deacetylase activity, resulting in the accumulation of acetylated histones, which could selectively repress the transcription of DPM3. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin could decrease the expression of DPM3 by inducing endoplasmic reticulum stress and the unfolded protein response, which can lead to the global attenuation of protein synthesis, including the biosynthesis of DPM3. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine may downregulate DPM3 by inhibiting DNA methyltransferase, leading to gene-specific hypomethylation and subsequent transcriptional repression of the DPM3 gene. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid could decrease the expression of DPM3 by binding to retinoic acid receptors, which can act as transcriptional repressors for specific genes, potentially including those involved in glycosylation processes like DPM3. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $107.00 | 3 | |
Spironolactone might inhibit the expression of DPM3 by antagonizing mineralocorticoid receptors, which may alter the transcription of a subset of genes, including those involved in the biosynthesis of membrane-bound oligosaccharides. | ||||||